Contributors

Cynthia J. Brame, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Elisabeth Buchdunger, PhD • Senior Research Investigator I, Oncology Research, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Thomas Buhl, PhD • Senior Research Investigator I, Musculoskeletal Diseases (MSD), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Renate Burger, PhD • Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Jennifer A. Caldwell-Busby, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Renaud Capdeville, md • Group Leader, Clinical Research, Novartis Oncology,

Novartis Pharma AG, Basel, Switzerland Alfredo C. Castro, PhD • Syntonix Pharmaceuticals, Waltham, MA Sandra W. Cowan-Jacob, PhD • Group Leader, Discovery Technologies,

Protein Structure Unit (DT/PSU), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Robert Cozens, PhD • Unit Head, Drug Discovery Pharmacology (DDP), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Henry Duewel, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Doriano Fabbro, PhD • Unit Head, In Vitro Profiling (IVP), and FIP Head of Signaling Pathways/Oncology Research, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Gabriele Fendrich, PhD • Research Investigator I, Discovery Technologies, Protein Structure Unit (DT/PSU), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Daniel Figeys, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Peter M. Finan, PhD • Novartis Horsham Research Centre, Horsham, UK Rainer Gamse, md • DA Project Management Director, MSD Management, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland xii

Contributors

Carlos García-Echeverría, PhD • Global Discovery Chemistry-Oncology, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Jürg A. Gasser, PhD • Senior Research Investigator I, Musculoskeletal Diseases (MSD), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Markus Glatt, PhD • Senior Research Investigator I, Musculoskeletal Diseases (MSD), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Martin Gramatzki, md • Division of Stem Cell and Immunotherapy II, and

Department of Medicine, University of Kiel, Kiel, Germany Jonathan Green, PhD • Senior Research Investigator II/NDS, Musculoskeletal Diseases (MSD), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland James D. Griffin, md • Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Carl-Henrik Heldin, phd • Ludwig Institute for Cancer Research, Uppsala, Sweden Christopher Hosfield, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Wolfgang Jahnke, PhD • Senior Research Investigator I/NLS, Discovery Technologies, Protein Structure Unit (DT/PSU), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Michaela Kneissel, PhD • Research Investigator II, Musculoskeletal Diseases (MSD), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Brett Larsen, msc • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Jarrod A. Marto, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Frank McCormick, md, PhD • UCSF Comprehensive Cancer Center,

University of California at San Francisco, San Francisco, CA Martin Missbach, PhD • Unit Head, Disease Area Bone, Muscle, and Gastrointestinal (BMG), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Michel F. Moran, PhD • McLaughlin Centre for Molecular Medicine,

Hospital for Sick Children, University of Toronto, Toronto, Canada Olga Ornatsky, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA

Contributors xiii

Terence O'Reilly, PhD • Senior Research Investigator I/NLS, Oncology, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Christopher Orsi, MEng • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Arne Östman, PhD • Cancer Center Karolinska, Karolinska Institute,

Stockholm, Sweden Mark Pearson, PhD • Research Investigator II, Oncology In Vitro Profiling (IVP), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Kristian Pietras, PhD • Ludwig Institute for Cancer Research, Stockholm, Sweden Paul Ramage, PhD • Group Leader, Discovery Technologies, Protein Structure Unit (DT/PSU), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Mark M. Ross, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Blanca Scheijen, PhD • Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Tobias Sjöblom, PhD • The Sydney Kimmel Comprehensive Cancer Center,

Johns Hopkins University, Baltimore, MD Mira SuSa, PhD • Senior Research Investigator I/NLS, Musculoskeletal Diseases (MSD), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Wilhelm Stark, PhD • Research Investigator I, Discovery Technologies, Protein Structure Unit (DT/PSU), Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland David R. Stover, PhD • Oncology Antibody Lab I, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland Anna Teti, PhD • University L'Aquilla, L'Aquilla, Italy Leticia M. Toledo-Sherman, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Thodoros Topaloglou, PhD • MDS Proteomics Inc., Toronto, Canada and Charlottesville, VA Stephen G. Ward, PhD • Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

Protein Tyrosine Kinases as Targets for Cancer and Other Indications

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment